Sol-Gel Technologies (NASDAQ: SLGL) has seen a significant boost in its stock price target, with HC Wainwright increasing it from $6.00 to $50.00. This adjustment, noted in a research report published on Monday, reflects a strong buy recommendation for the stock. Analysts at HC Wainwright have also provided future earnings estimates for Sol-Gel Technologies, predicting losses of ($2.09) earnings per share (EPS) for Q3 2025, and a return to profitability with an estimated $0.40 EPS in Q4 2025.
In addition to HC Wainwright’s analysis, several other financial research firms have shared their perspectives on Sol-Gel Technologies. Weiss Ratings reaffirmed a “hold (c-)” rating in a note on October 8, while Wall Street Zen upgraded the stock to a “buy” rating on September 13. Currently, the consensus rating on the stock is classified as a “Moderate Buy,” with an average target price matching HC Wainwright’s estimate of $50.00.
Recent Financial Performance
Sol-Gel Technologies recently reported its quarterly earnings on August 15, 2023, revealing a surprising $4.17 EPS, which exceeded analysts’ expectations of ($0.67) by $4.84. The company also reported a revenue of $17.26 million, significantly higher than the anticipated $2.86 million. Despite these positive results, the firm has faced challenges, including a negative return on equity of 11.80% and a net margin of 14.25%.
Looking ahead, sell-side analysts forecast that Sol-Gel Technologies will report an EPS of (0.28) for the current fiscal year, indicating ongoing financial challenges as the company navigates its market.
About Sol-Gel Technologies
Sol-Gel Technologies Ltd., alongside its subsidiary Sol-Gel Technologies Inc., is focused on developing topical dermatological treatments for patients with severe skin conditions in Israel. Among its offerings are Twyneo, a once-daily, non-antibiotic topical cream aimed at treating acne vulgaris, and Epsolay, designed for the treatment of papulopustular rosacea.
The recent upward revision of the price target, combined with promising earnings results, positions Sol-Gel Technologies as a notable player in the dermatological market, attracting interest from investors and analysts alike. As the company continues to develop its product portfolio, market watchers will be keen to see how these changes impact its financial trajectory in the coming quarters.
